Progressive Care (OTCQB: RXMD), a personalized healthcare services and technology provider, is reporting its financial results for the first quarter ended March 31, 2023. According to the report, the company saw record quarterly revenue; the report showed a $11.4 million revenue for the first quarter, a 13% increase from the first quarter ended March 31, 2022. Other highlights include total pharmacy revenue increasing by $1.3 million, or 13%; prescription revenue increased by $1.8 million, or 21%, to total $10.4 million during the first quarter of 2023; 340B contract revenue for the quarter was $1.6 million, an increase of $1.2 million; gross profit margin increased 28% for the three months ended March 31, 2023; and cash balance at the end of the quarter was an estimated $7.5 million compared to $6.7 million at December 31, 2022. The company also noted key organizational milestones reached during the quarter, including the appointment of Dr. Pamela Roberts as COO and the successful completion of $1 million investment from NextPlat Corp. “We had a net loss of approximately $0.1 million and $1.4 million for the three months ended March 31, 2023 and 2022, respectively,” the report stated. “The decrease in net loss is attributable to nonoperating items primarily recorded in the prior year period such as the adverse change in the fair value of derivative liabilities, as well as the decrease in interest expense period over period.”

To view the full press release, visit https://ibn.fm/3rbZw

About Progressive Care

Progressive Care, through its subsidiaries, is a Florida health services organization and provider of Third-Party Administration (TPA), data management, COVID-19 related diagnostics and vaccinations, 340B contracted pharmacy services, prescription pharmaceuticals, compounded medications, provider of telepharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management. For more information about the company, visit www.ProgressiveCareUS.com

NOTE TO INVESTORS: The latest news and updates relating to RXMD are available in the company’s newsroom at https://ibn.fm/RXMD

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork